Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TVTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sparsentan (RE-021) FDA approved Feb 2023 · Filspari |
Proteinuria | Phase 4 · NCT07219121 | Active not recruiting |
| Fosmetpantotenate | Pantothenate Kinase-Associated Neurodegeneration | Phase 3 · NCT03041116 | Terminated |
| Pegtibatinase | Homocystinuria | Phase 3 · NCT06247085 | Recruiting |
| No sparsentan | Proteinuric Renal Disease | Phase 1 · NCT07224776 | Recruiting |
Also used in these trials (approved or third-party drugs, not TVTX's own candidates): Dapagliflozin, Irbesartan.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TVTX holds $471.8M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TVTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 5,707,883 | 5.95% | 2026-09-30 |
| BANK OF AMERICA CORP /DE/ | Institution (13G, 5%+) | 5,439,155 | 5.67% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 4,699,424 | 4.90% | 2026-03-31 |
| Eric M Dube CHIEF EXECUTIVE OFFICER, Director · +351,425 options |
Insider | 432,886 | 0.45% | 2026-10-15 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER · +78,061 options |
Insider | 117,066 | 0.12% | 2026-09-15 |
| Elizabeth E Reed Chief Legal Officer and GC · +4,250 options |
Insider | 105,389 | 0.11% | 2026-09-15 |
| Jula Inrig EVP, Head of R&D & CMO · +82,355 options |
Insider | 100,491 | 0.10% | 2026-09-15 |
| William E. Rote Chief Research Officer · +4,250 options |
Insider | 98,197 | 0.10% | 2026-09-15 |
| Jeffrey A Meckler Director · +12,000 options |
Insider | 91,500 | 0.10% | 2026-09-10 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER · +4,250 options |
Insider | 87,508 | 0.09% | 2026-09-15 |
| Gary A Lyons Director · +12,000 options |
Insider | 61,500 | 0.06% | 2026-08-17 |
| Timothy Coughlin Director · +12,000 options |
Insider | 56,250 | 0.06% | 2026-06-12 |
Share count 95,992,155 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-04-13 | FILSPARI | NDA | +1.7% | +6% | +40.8% |
| 2026-01-13 | — | sNDA | -0.8% | -14.6% | -18.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →